1,25-Dihydroxyvitamin D3-differentiated human promyelocytic leukaemia cells (HL-60) can kill antibody-coated tumour cells (K562).
The active metabolite of vitamin D3, 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3), was tested for the ability to differentiate promyelocytic leukaemia cells (HL-60) and histiocytic lymphoma cells (U937) into cytotoxic effector cells against K562 leukaemia cells. A concentration of 10(-6) M 1,25(OH)2D3 differentiated HL-60 cells into substrate-adherent monocyte-like cells with cytolytic activity against antibody-coated K562 cells. These differentiated HL-60 cells were not able to lyse uncoated K562 cells in an 18-h Cr-release assay. Similar treatment of the U937 cells with 1,25(OH)2D3 did not make them cytolytic towards K562 cells. These data indicate that 1,25(OH)2D3 can differentiate HL-60 cells to mature monocytes with cytolytic activity against antibody-coated leukaemia cells.
D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects*; D002117:Calcitriol / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology
D002117:Calcitriol